ANEB - MCAP CO - Anebulo Pharmaceuticals

Anebulo Pharmaceuticals (ANEB) creates unique antidotes for cannabinoid intoxication, securing a monopoly position through its patents. The business targets the B2B segment of emergency departments for the therapy of acute psychosis. A clear inventory system and streamlined component delivery guarantee development stability. The asset's market capitalization is . The asset's price trajectory is illustrated in the chart below.

When screening for issuer reliability, enterprise value serves as the key filter. The market capitalization of a company is calculated as the product of the current share price and the total number of outstanding securities. For Anebulo Pharmaceuticals (ANEB), this metric reflects a speculative valuation of antidote potential in the absence of revenue and positive FCF. The market capitalization trend of Anebulo Pharmaceuticals (ANEB) demonstrates the asset's market weight amid high R&D expenditures.